Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel with intraperitoneal paclitaxel for pancreatic cancer with peritoneal metastasis
jRCTs031180095Phase 2Active, not recruiting
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) and peritoneal carcinomatosis (PC). Primary endpoints: Dose-limiting toxicity (DLT) and Overall survival. Started Dec 2017; status: active, not recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on jRCTs031180095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180095.